Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Rating Upgraded by Wall Street Zen

Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Sunday.

A number of other research firms have also issued reports on CPRX. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Thursday, June 5th. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $33.20.

Catalyst Pharmaceuticals Stock Up 1.4%

CPRX opened at $20.05 on Friday. The stock has a fifty day moving average of $20.53 and a 200-day moving average of $22.29. The firm has a market capitalization of $2.45 billion, a P/E ratio of 12.15, a PEG ratio of 0.80 and a beta of 0.85. Catalyst Pharmaceuticals has a 12-month low of $19.15 and a 12-month high of $26.58.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 30,000 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $20.30, for a total transaction of $609,000.00. Following the completion of the transaction, the insider owned 271,039 shares in the company, valued at $5,502,091.70. This trade represents a 9.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Richard J. Daly sold 22,970 shares of the firm’s stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $20.62, for a total transaction of $473,641.40. Following the transaction, the chief executive officer owned 226,794 shares of the company’s stock, valued at approximately $4,676,492.28. This represents a 9.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 243,970 shares of company stock worth $4,927,241 in the last three months. 10.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Algert Global LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 1.0% in the 1st quarter. Algert Global LLC now owns 48,390 shares of the biopharmaceutical company’s stock worth $1,173,000 after acquiring an additional 470 shares in the last quarter. Mission Wealth Management LP raised its position in shares of Catalyst Pharmaceuticals by 5.0% during the 2nd quarter. Mission Wealth Management LP now owns 10,620 shares of the biopharmaceutical company’s stock valued at $230,000 after acquiring an additional 510 shares during the last quarter. Hancock Whitney Corp raised its position in shares of Catalyst Pharmaceuticals by 1.4% during the 1st quarter. Hancock Whitney Corp now owns 38,847 shares of the biopharmaceutical company’s stock valued at $942,000 after acquiring an additional 525 shares during the last quarter. New York State Teachers Retirement System grew its holdings in shares of Catalyst Pharmaceuticals by 0.4% in the 2nd quarter. New York State Teachers Retirement System now owns 149,887 shares of the biopharmaceutical company’s stock valued at $3,253,000 after buying an additional 577 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of Catalyst Pharmaceuticals by 26.2% in the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 579 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.